Drug intelligence / Profile preview

influenza vaccine, inactivated, subunit, trivalent

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**Influenza vaccine, inactivated, subunit, trivalent** is a **seasonal vaccine** containing purified hemagglutinin (HA) subunits from three influenza virus strains (two A subtypes, typically H1N1 and H3N2, and one B lineage, most recently B/Victoria lineage). It is **manufactured by inactivating virus grown in eggs or cell culture, splitting the viral particles, and further purifying subunits, chiefly the HA protein**. This vaccine induces immunity primarily by stimulating antibody production against the influenza virus HA and, to a lesser extent, NA proteins, thereby preventing infection or reducing disease severity. It is administered annually, with protection tailored to circulating viral strains under WHO and FDA recommendations. Indicated for all eligible individuals 6 months and older, especially in populations at higher risk of influenza complications[1][3][6][7].

Brand names
InfluvacFluvirinAgrifluFlucelvax
Other names
trivalent inactivated influenza vaccine subunittrivalent inactivated subunit influenza vaccineTIV subunit
02

Targets

TCR (T-cell receptor (TCR) recognizing influenza viral epitope)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on influenza vaccine, inactivated, subunit, trivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza vaccine, inactivated, subunit, trivalent.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call